From: Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus
PCR for HCV, week 24
Ribavirin dose reduction or discontinuation
Chi-square
Yes
No
Total
N
%
X2
P-value
Positive
0
0.00
2
4.35
4.00
0.181
0.670
Negative
4
100.00
44
95.65
48
96.00
46
50